HC Wainwright Predicts OptiNose FY2029 Earnings

OptiNose, Inc. (NASDAQ:OPTN) – Investment analysts at HC Wainwright issued their FY2029 earnings estimates for OptiNose in a research note issued to investors on Friday, January 3rd. HC Wainwright analyst M. Caufield expects that the company will post earnings per share of $1.41 for the year. HC Wainwright has a “Buy” rating and a $18.00 price target on the stock. The consensus estimate for OptiNose’s current full-year earnings is ($0.20) per share.

Separately, Piper Sandler reduced their target price on OptiNose from $45.00 to $15.00 and set an “overweight” rating for the company in a report on Wednesday, November 13th.

OptiNose Stock Down 2.6 %

OPTN opened at $5.96 on Monday. The firm has a market cap of $59.96 million, a PE ratio of -21.28 and a beta of -0.15. The business has a fifty day simple moving average of $7.69 and a 200-day simple moving average of $11.70. OptiNose has a fifty-two week low of $4.82 and a fifty-two week high of $31.50.

Institutional Trading of OptiNose

Large investors have recently added to or reduced their stakes in the company. Massachusetts Financial Services Co. MA increased its holdings in shares of OptiNose by 2.9% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 2,920,309 shares of the company’s stock valued at $3,037,000 after purchasing an additional 81,233 shares during the period. XTX Topco Ltd purchased a new position in OptiNose during the second quarter valued at approximately $88,000. Great Point Partners LLC increased its stake in OptiNose by 56.2% in the 2nd quarter. Great Point Partners LLC now owns 13,727,097 shares of the company’s stock valued at $14,276,000 after buying an additional 4,940,779 shares during the period. Squarepoint Ops LLC increased its stake in OptiNose by 173.7% in the 2nd quarter. Squarepoint Ops LLC now owns 171,610 shares of the company’s stock valued at $178,000 after buying an additional 108,903 shares during the period. Finally, Nantahala Capital Management LLC lifted its position in OptiNose by 442.3% in the 2nd quarter. Nantahala Capital Management LLC now owns 13,418,740 shares of the company’s stock worth $14,425,000 after buying an additional 10,944,444 shares in the last quarter. 85.60% of the stock is owned by institutional investors and hedge funds.

OptiNose Company Profile

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.